ANGO — Angiodynamics Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual income statement for Angiodynamics, fiscal year end - May 31st, USD millions except per share, conversion factor applied.

	2021 May 31st	2022 May 31st	2023 May 31st	2024 May 31st	2025 May 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	291	316	339	304	292
Cost of Revenue
Gross Profit	157	166	174	155	158
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	326	345	390	496	332
Operating Profit	-35.3	-28.5	-51.2	-192	-40
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-36.1	-29.9	-54.4	-192	-34
Provision for Income Taxes
Net Income After Taxes	-31.5	-26.5	-52.4	-184	-34
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-31.5	-26.5	-52.4	-184	-34
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-31.5	-26.5	-52.4	-184	-34
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.48	-0.53	-0.831	-2.03	-0.584